

DEPARTMENT OF THE AIR FORCE
USAF MEDICAL CENTER, WRIGHT-PATTERSON (AFLC)
WRIGHT-PATTERSON AIR FORCE BASE, OHIO 45433



REPLY TO
ATTN OF Med Cen/SGH

29 September 1976

SUBJECT: Clinical Investigation Proposals - No. 488, (489) 634

AIR1.941130.050m

TO: Hq USAF/SGPR

1. In accordance with paragraph 3b(8) of AFR 169-6 and Hq USAF/SGPR Ltr, Clinical Investigation Proposal No. 488: Clinical Investigation of Gallium-67 Citrate, 19 Jul 76, final progress report on this investigation is attached (Atch 1).
2. Progress reports are attached for Clinical Investigation Proposal No. 489 - Indium-III DTPA for Cisternography and No. 634 - PHASE III EVALUATION OF TECHNETIUM-99m ELECTROLYTICALLY LABELED HUMAN SERUM ALBUMIN, (Atchs 2 & 3).


GUNTER R. MENG, Colonel, USAF, MC
Commander

- 3 Atch
1. Final Progress Report, No. 488
 2. Progress Report, No. 489
 3. Progress Report, No. 634

Cy to: AFLC/SG
AMD/RD

AFLC - Lifeline of the Aerospace Team

DEPARTMENT OF THE AIR FORCE
USAF MEDICAL CENTER, WRIGHT-PATTERSON (AFLC)
WRIGHT-PATTERSON AIR FORCE BASE, OHIO 45433




REF ID: A77402
ATTN: Med Cen/SGHH

20 September 1976

SUBJECT: Progress Report: Clinical Investigation Proposal #489

TO: Hq USAF/SGPR

1. ¹¹¹InDTPA is used to establish the diagnosis of low pressure hydrocephalus, to document the presence of arachnoid blocks, cysts and for the analysis of ventricular shunt patency. The study is being used at present in these selected cases.
2. No funds are allotted for this study and the material is purchased with the Nuclear Medicine Department operational funds.
3. Completion date of this project will be when ¹¹¹InDTPA is no longer an investigational drug and becomes a well-accepted procedure.


SAMUEL SOSTRE, Major, USAF, MC
Chairman, Department of Nuclear Medicine

Cy to: AFLC/SG
AMD/RD

AFLC - Lifeline of the Aerospace Team

Atch 2

DEPARTMENT OF THE AIR FORCE
USAF MEDICAL CENTER, WRIGHT-PATTERSON (AFLC)
WRIGHT-PATTERSON AIR FORCE BASE, OHIO 45433



REPLY TO
ATTN OF: SGHH

18 March 1975

SUBJECT: Progress Report: Clinical Investigation Proposal #489

TO: HQ USAF/SGPR

1. At present the usage of ¹¹¹In-DTPA for cisternography is governed by USAF Clinical Investigation proposals. This is necessitated by their classification by the Food and Drug Administration as an investigative new drug. ¹¹¹In-DTPA is used in our laboratory to establish the diagnosis of low-pressure hydrocephalus. It is also useful for the documentation of arachnoid blocks and arachnoid cysts but it's main clinical usefulness is as stated above, to differentiate patients with dementia from those with low-pressure hydrocephalus. This procedure is not frequently used and we have performed only 8 such studies since it was instituted in this hospital in 1973.
2. No funds are allotted for this study and the material is purchased with the Nuclear Medicine Department operational funds.
3. As this is a useful tool, when indicated, we will continue to perform the tests until it becomes a well accepted procedure. So, date of completion will be when ¹¹¹In-DTPA for cisternography is eliminated from the list of investigative new drugs.
4. None.

John J. Halki
JOHN J. HALKI, Colonel, USAF, MC
Commander

Copy to: AFPC/SG
AMD/RD

AFLC - Lifeline of the Aerospace Team